Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Bunkyo, TokyoFounded 19481,086 employeesWebsite
A pharmaceutical company with strengths in dermatology and orthopedics. It develops and supplies prescription medicines, addressing specialized treatment needs through its research capabilities.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Products Business | 97% | ¥74.3B | ¥-2.3B | -3.1% |
| Real Estate Business | 3% | ¥2.5B | ¥1.4B | 54.1% |
Close (Oct 30, 2026)
¥3,830+5.2% (1Y)
Kaken +5.2% over 1Y, 7.7pt below the industry average (23 companies, +12.9%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥76.9B | ¥-899M | ¥2.1B | ¥178.2B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
